Brown, Lisle/Cummings’s ARK Genomic Revolution ETF ARKG Stock Holding History

Brown, Lisle/Cummings’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.59K	Hold	325	–	–	﹤0.01%	600
2025 Q4	$9.41K	Hold	325	–	–	﹤0.01%	506
2025 Q3	$9.03K	Hold	325	–	–	﹤0.01%	515
2025 Q2	$7.91K	Hold	325	–	–	﹤0.01%	525
2025 Q1	$6.75K	Sell	325 -75	-19%	-$1.88K	﹤0.01%	532
2024 Q4	$9.42K	Buy	400 +21	+6%	+$517	﹤0.01%	489
2024 Q3	$9.7K	Hold	379	–	–	﹤0.01%	470
2024 Q2	$8.9K	Buy	379 +129	+52%	+$3.26K	﹤0.01%	466
2024 Q1	$7.19K	Hold	250	–	–	﹤0.01%	461
2023 Q4	$8.2K	Hold	250	–	–	﹤0.01%	458
2023 Q3	$6.96K	Hold	250	–	–	﹤0.01%	444
2023 Q2	$8.52K	Hold	250	–	–	﹤0.01%	432
2023 Q1	$7.52K	Buy	250 +75	+43%	+$2.32K	﹤0.01%	428
2022 Q4	$4.94K	Buy	175 +75	+75%	+$2.38K	﹤0.01%	442
2022 Q3	$3.29K	Hold	100	–	–	﹤0.01%	450
2022 Q2	$3.15K	Hold	100	–	–	﹤0.01%	433
2022 Q1	$4.59K	Buy	+100	New	+$4.77K	﹤0.01%	433

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Brown, Lisle/Cummings's ARKG Position: Q1 2026 in Review

Brown, Lisle/Cummings held its ARK Genomic Revolution ETF (ARKG) position steady in Q1 2026 at 325 shares worth $8.59K. The position accounts for ﹤0.01% of the portfolio, ranked #600.

Brown, Lisle/Cummings first reported a position in ARKG in Q1 2022 and has held it in 17 quarters since. The position peaked at $9.7K in Q3 2024. 219 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

Brown, Lisle/Cummings held 325 shares of ARK Genomic Revolution ETF worth $8.59K as of Q1 2026.
Brown, Lisle/Cummings left its ARK Genomic Revolution ETF share count unchanged in Q1 2026.
ARK Genomic Revolution ETF made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #600 holding.
Brown, Lisle/Cummings first reported a position in ARK Genomic Revolution ETF in Q1 2022 and has held it in 17 quarters since.
Brown, Lisle/Cummings's ARK Genomic Revolution ETF position peaked at $9.7K in Q3 2024.
219 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.